Erythropoiesis stimulating agents approaches to modulate activity

摘要: Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due relatively short half-life molecule (approximately 8 hours), frequent dosing may be required achieve hemoglobin levels. Therefore, a need was identified some anemic patient populations erythropoiesis stimulating with longer half-lives that less dosing. This led development second generation molecules which are modified versions rHuEPO improved pharma-cokinetic pharmacodynamic properties darbepoetin alfa, hyperglycosylated analog rHuEPO, pegzyrepoetin, pegylated rHuEPO. Third molecules, peginesatide, peptide mimetics have no sequence homology also recently developed. The various molecular, pharmacokinetic, these other will discussed this review.